Profiling of HCAR1 signalling reveals Gα <sub>i/o</sub> and Gα <sub>s</sub> activation without β‐arrestin recruitment and the discovery of an allosteric agonist
These findings expand our understanding of HCAR1 signalling and introduce new molecular tools for probing its physiological and pathological roles. The characterized ligands may support future therapeutic strategies targeting HCAR1 in metabolic disorders while informing approaches to mitigate potential oncogenic effects.
Authors
- Emilia Gvozdenović
- Kenneth L. Granberg (ORCID: https://orcid.org/0000-0003-3655-741X)
- Simon Lind (ORCID: https://orcid.org/0000-0001-6469-4345)
- Linda C. Johansson (ORCID: https://orcid.org/0000-0003-4776-5142)
- Kristina Nilsson
- Michel Bouvier
- Shane C. Wright
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Institute for Research in Immunology and Cancer (CA)
- AstraZeneca (Sweden) (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1111/bph.70312
- Citations
- 1
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- AstraZeneca
- Jeanssons Stiftelser
- Svenska Sällskapet för Medicinsk Forskning
- Karolinska Institutet
- Novo Nordisk
- Vetenskapsrådet
- Novo Nordisk Fonden
- Stiftelsen för Strategisk Forskning
- Natural Sciences and Engineering Research Council of Canada
- Institute of Circulatory and Respiratory Health